Fennec Pharmaceuticals (FENC) CCO awarded 168 common shares in Form 4

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported a compensation-related stock event. On May 31, 2026, Evans acquired 168 Common Shares at a stated price of $0.00 per share, characterized as a grant, award, or similar acquisition.

According to the filing, these shares represent a release from restriction on shares originally awarded on March 28, 2025. Following this transaction, Evans directly holds a total of 21,015 Common Shares of Fennec Pharmaceuticals, reflecting a routine increase in his equity-based compensation holdings rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Evans Terry L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 21,015 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 168 Common Shares Grant price: $0.00 per share Shares owned after: 21,015 Common Shares +1 more

4 metrics

Shares granted 168 Common Shares Grant/award acquisition on May 31, 2026

Grant price $0.00 per share Stated transaction price for 168-share award

Shares owned after 21,015 Common Shares Direct holdings following the transaction

Transactions acquiring shares 1 transaction Non-derivative, grant/award acquisition

Key Terms

Grant, award, or other acquisition, Common Shares, released from restriction

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Shares financial

"security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/01/2026 - 04:07 PM Accepted by SEC EDGAR 06/01/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Terry L

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	05/31/2026		A		168	A	$0	21,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Terry Evans	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Terry L. Evans?

Fennec Pharmaceuticals reported that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares as a grant or award. The shares were received at a stated price of $0.00 per share, reflecting equity-based compensation rather than an open-market stock purchase.

How many FENC shares did Terry L. Evans receive and at what price?

Terry L. Evans received 168 Fennec Pharmaceuticals Common Shares in this transaction. The filing lists a transaction price of $0.00 per share, indicating the shares were granted as compensation, not bought in the market at a cash purchase price.

What is Terry L. Evans’ total Fennec Pharmaceuticals (FENC) shareholding after this Form 4?

After the reported transaction, Terry L. Evans directly holds 21,015 Common Shares of Fennec Pharmaceuticals. This total includes the 168 shares released from restriction, and represents his updated direct ownership position as disclosed in the Form 4 filing.

What is the nature of the 168 FENC shares reported for Terry L. Evans?

The 168 shares are described as a grant, award, or other acquisition of Common Shares. A footnote explains they represent shares released from restriction that were originally awarded on March 28, 2025, making this a vesting-type event rather than a market trade.

Did Terry L. Evans buy or sell FENC shares on the open market in this filing?

The filing does not show any open-market purchases or sales by Terry L. Evans. Instead, it reports an acquisition coded as a grant or award, with 168 Common Shares received at a stated price of $0.00 per share as part of his compensation.